Clinical trials: First Line Treatment
Cancer of Unknown Primary Site
Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
This study is a prospective, real world study.The objective is to observe the diagnosis and first-line treatment of Chinese patients with cancer of unknown primary, and collect the clinicopathological characteristics, treatment…
- Trial name
- NCT04952103
- Testing
- no intervention
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Carcinoma, Squamous Cell
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The aim of this prospective, observational, multicenter, post-marketing study is to evaluate the safety and efficacy of Cetuximab (Erbitux) in combination with platinum based chemotherapy, in the first line therapy of recurrent/…
- Trial name
- NCT01142869
- Testing
- Cetuximab
- Where
- 28 sites in India
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non-Small Cell Carcinoma of Lung, TNM Stage 4, Radiation Therapy
Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients
study the effect of radiotherapy to the primary lesion after first line systemic therapy in metastatic non-small cell lung cancer patients.
- Trial name
- NCT04776083
- Testing
- first line systemic therapy, 3D radiotherapy or IMRT
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Menoufia University
Lung Cancer
Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer
RATIONALE: Marimastat may stop the growth of lung cancer by stopping blood flow to the tumor. It is not yet known if marimastat is an effective treatment for small cell lung cancer.
- Trial name
- NCT00003011
- Testing
- marimastat
- Where
- 38 sites in Canada
- Volunteers
- 555 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive…
- Trial name
- FACT (NCT00256698)
- Testing
- Fulvestrant, Anastrozole
- Where
- 85 sites in Canada, Costa Rica and 10 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Graft vs Host Disease
Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease
Steroids are still the first line treatment for established severe acute-graft-versus-host-disease (aGVHD), with a response rate of 30-50%, and there is no established and effective therapy for severe steroid-refractory (aGVHD).
- Trial name
- NCT02770430
- Testing
- mesenchymal stem cells, conventional treatment
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Ovarian Cancer
Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer
This is a single-center, prospective, single-arm clinical trial to evaluate the efficacy and safety of Huaier granules in combination with immunotargeted agents in postoperative patients with ovarian cancer.
- Trial name
- NCT05749211
- Testing
- Huaier granule
- Volunteers
- 59 people
- Sponsor
- Ruijin Hospital
Nasopharyngeal Cancinoma (NPC)
GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) has a low incidence rate in children, accounting for only 1-2% of pediatric tumors. However, it is prone to metastasis, and most patients are already in advanced stages at the time of diagnosis.
- Trial name
- NCT06605131
- Testing
- GP+Toripalimab+CCRT, GP+CCRT
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms
An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
This is an open-label, non-randomized, prospective, multicentric, Phase IV study evaluating FOLFIRI/ FOLFOX plus cetuximab in the first-line therapy of subjects with KRAS wild-type metastatic CRC.
- Trial name
- NCT01134666
- Testing
- Cetuximab
- Where
- 40 sites in India
- Volunteers
- 165 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Congenital Heart Disease
Platelets or Fibrinogen as First-line Treatment for Bleeding During Pedatric Heart Surgery
The study aims to test whether platelet transfusion or fibrinogen concentrate is the most effective treatment of intraoperative bleeding, when performing open heart surgery with cardiopulmonary bypass on children with congenital…
- Trial name
- NCT04807621
- Testing
- Platelet transfusion, Fibrinogen concentrate
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Sahlgrenska University Hospital
Ovarian Cancer, HER2
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Ovarian cancer exhibits the highest mortality rate among gynecological malignancies. Currently, the combination of paclitaxel and carboplatin remains the standard first-line chemotherapy regimen for neoadjuvant or postoperative…
- Trial name
- NCT07285941
- Testing
- RC48 + Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Lymphadenopathy, Stage I Testicular Seminoma
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma.
- Conditions
- Lymphadenopathy, Stage I Testicular Seminoma, Stage II Testicular Seminoma
- Trial name
- NCT02537548
- Testing
- Laboratory Biomarker Analysis, Retroperitoneal Lymph Node Dissection
- Where
- 14 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Southern California
Post-transplantation Lymphoproliferative Disorder
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)
Post-transplantation lymphoproliferative disorder (PTLD) develops in one to ten per cent of transplant recipients and can be EBV-associated.
- Trial name
- NCT01458548
- Testing
- Rituximab, CHOP
- Where
- 4 sites in Australia, France and 2 more
- Volunteers
- 70 people
- Sponsor
- Charite University, Berlin, Germany
HCC
Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
This is a phase II, open-label, single-arm clinical study of nimotuzumab in combination with immune checkpoint inhibitors in patients with advanced liver cancer who have failed first-line therapy
- Trial name
- NCT06413017
- Testing
- Nimotuzumab, ICIs(Immune checkpoint inhibitors)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples
Bladder Cancer
Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combination chemotherapy combined with transurethral resection may kill more tumor cells.
- Trial name
- NCT00003640
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Rhinosinusitis
Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)
This study was conducted to compare the effectiveness and safety of mometasone nasal spray once daily or twice daily with amoxicillin or with placebo in treating the signs and symptoms of acute rhinosinusitis.
- Trial name
- NCT00751075
- Testing
- mometasone furoate nasal spray (MFNS), MFNS, Amoxicillin
- Volunteers
- 981 people
- Sponsor
- Organon and Co
Breast Cancer
Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer
Primary Objectives: 1. To validate the prognostic significance of circulating tumor cells (CTCs) in patients with newly diagnosed metastatic breast cancer (MBC). 2.
- Trial name
- NCT00493350
- Testing
- Blood Sample
- Where
- United States
- Volunteers
- 660 people
- Sponsor
- M.D. Anderson Cancer Center
Immune Thrombocytopenia
Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate
This is a study of two treatment pathways [Standard steroid treatment versus combined steroid and Mycophenolate (MMF)] for subjects with newly diagnosed Immune Thrombocytopenia (ITP).
- Trial name
- FLIGHT (NCT03156452)
- Testing
- Mycophenolate Mofetil, Prednisolone
- Where
- United Kingdom
- Volunteers
- 123 people
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Acute Myeloid Leukemia
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed acute myeloid leukemia.
- Trial name
- NCT06068621
- Testing
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7"
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital